EVRのチャート
EVRの企業情報
| symbol | EVR |
|---|---|
| 会社名 | Evercore Partners Inc （EVERCORE INC） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 投資銀行_証券サ―ビス 金融（Financials） |
| 概要 | エバーコア(Evercore Inc)(旧名:Evercore Partners Inc.)は独立系の投資銀行顧問会社である。同社は取引に関して投資銀行顧客にアドバイスを提供し、機関投資家に、独自の活動によって生み出された株式調査、販売および取引の実行を提供している。同社はまた、純資産高および機関投資家に対して投資管理サービスを提供している。同社は北米、ヨーロッパ、南米、アジアに28の事務所と関連事務所を持ち、集中的かつカスタマイズされたアプローチを通じて、世界中の顧客にサービスを提供する。 エバ―コア・パ―トナ―ズは米国の投資銀行顧問サ―ビス持株会社。主なサ―ビスは、企業の合併、買収、売却、再編及び、融資、株式公開、私募、第三者割当、その他の戦略的取引に関してのアドバイス。また、組織の資産管理、財産管理、専門的な投資運用、独立系信託サ―ビス、未公開株式投資ファンドの運用などに助言を提供。本社はニューヨーク州。 Evercore Partners Inc. is a premier global independent investment banking advisory firm. The company is dedicated to helping its clients achieve superior results through trusted independent and innovative advice on matters of strategic significance to boards of directors, management teams and shareholders, including mergers and acquisitions, strategic shareholder advisory, restructurings, and capital structure. Evercore also assists clients in raising public and private capital and delivers equity research and equity sales and agency trading execution, in addition to providing wealth and investment management services to high net worth and institutional investors. Founded in 1995, the Firm is headquartered in New York and maintains offices and affiliate offices in major financial centers in the Americas, Europe, the Middle East and Asia. |
| 本社所在地 | 55 East 52nd Street 38th floor New York NY 10055 USA |
| 代表者氏名 | John S. Weinberg |
| 代表者役職名 | Executive Chairman of the Board |
| 電話番号 | +1 212-857-3100 |
| 設立年月日 | 38534 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 1475人 |
| url | www.evercore.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） 576.48400 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 4508.51500 |
| 売上高 | （百万ドル） 2082.47600 |
| 企業価値(EV) | （百万ドル） 3604.28900 |
| 当期純利益 | （百万ドル） 377.63900 |
| 決算概要 | BRIEF: For the fiscal year ended 31 December 2018 Evercore Inc revenues increased 21% to $2.08B. Net income before extraordinary items increased 41% to $377.6M. Revenues reflect Investment Banking segment increase of 23% to $2.01B United States segment increase of 33% to $1.59B Latin America segment increase from $15.3M to $32.9M Europe segment increase of 4% to $438.6M. |
EVRのテクニカル分析
EVRのニュース
Evercore ISI Downgrades Qualtrics to In Line 2023/03/06 15:45:02 Investing.com
https://www.investing.com/news/pro/evercore-isi-downgrades-qualtrics-to-in-line-432SI-3023100
Akero Therapeutics Inc. (AKRO) is an excellent investment, but the stock is overvalued/undervalued right now 2023/03/03 13:00:00 US Post News
Within its last year performance, AKRO rose by 172.10%, with highs and lows ranging from $54.88 to $7.52, whereas the simple moving average jumped by 61.43% in the last 200 days. On January 27, 2023, Morgan Stanley Upgraded Akero Therapeutics Inc. (NASDAQ: AKRO) to Overweight. A report published by Evercore ISI on September 14, 2022, […]
Evercore ISI Upgrades Neurocrine Bio. to Outperform, ''We believe 2023 Ingrezza guidance will prove to be conservative'' 2023/03/03 11:42:02 Investing.com
https://www.investing.com/news/pro/evercore-isi-upgrades-neurocrine-bio-to-outperform-we-believe-2023-ingrezza-guidance-will-prove-to-be-conservative-432SI-3021520
Exclusive: Cybersecurity firm OneSpan explores sale, sources say 2023/03/02 17:42:11 Channel NewsAsia
NEW YORK : OneSpan Inc, a U.S. cybersecurity tools vendor that has become the target of activist hedge funds such as Legion Partners Asset Management, is exploring options that include a sale of the company, people familiar with the matter said. OneSpan is working with investment bank Evercore Inc on a sa
OneSpan gains on report it''s exploring potenial sale 2023/03/02 17:41:08 Seeking Alpha
OneSpan (OSPN) jumped 10% on a report that the cybersecurity firm is exploring options, including a possible sale.OneSpan (OSPN) is working with Evercore ISI on a sales process that…
Akero Therapeutics Inc. (AKRO) is an excellent investment, but the stock is overvalued/undervalued right now 2023/03/03 13:00:00 US Post News
Within its last year performance, AKRO rose by 172.10%, with highs and lows ranging from $54.88 to $7.52, whereas the simple moving average jumped by 61.43% in the last 200 days. On January 27, 2023, Morgan Stanley Upgraded Akero Therapeutics Inc. (NASDAQ: AKRO) to Overweight. A report published by Evercore ISI on September 14, 2022, […]
Evercore ISI Upgrades Neurocrine Bio. to Outperform, ''We believe 2023 Ingrezza guidance will prove to be conservative'' 2023/03/03 11:42:02 Investing.com
https://www.investing.com/news/pro/evercore-isi-upgrades-neurocrine-bio-to-outperform-we-believe-2023-ingrezza-guidance-will-prove-to-be-conservative-432SI-3021520
Exclusive: Cybersecurity firm OneSpan explores sale, sources say 2023/03/02 17:42:11 Channel NewsAsia
NEW YORK : OneSpan Inc, a U.S. cybersecurity tools vendor that has become the target of activist hedge funds such as Legion Partners Asset Management, is exploring options that include a sale of the company, people familiar with the matter said. OneSpan is working with investment bank Evercore Inc on a sa
OneSpan gains on report it''s exploring potenial sale 2023/03/02 17:41:08 Seeking Alpha
OneSpan (OSPN) jumped 10% on a report that the cybersecurity firm is exploring options, including a possible sale.OneSpan (OSPN) is working with Evercore ISI on a sales process that…
ONESPAN INC WORKING WITH EVERCORE INC TO EXPLORE A SAL 2023/03/02 17:34:21 Longport
(marketscreener.com) EXCLUSIVE-ONESPAN INC WORKING WITH EVERCORE INC TO EXPLORE A SALE - SOURCES https://www.marketscreener.com/news/latest/ONESPAN-INC-WORKING-WITH-EVERCORE-INC-TO-EXPLORE-A-SAL-8230--43141270/?
Evercore ISI Removes Apple From Tactical Outperform List 2023/02/03 16:42:02 Investing.com
https://www.investing.com/news/pro/evercore-isi-removes-apple-from-tactical-outperform-list-432SI-2995180
Thermo Fisher Scientific To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday 2023/02/02 15:36:38 Benzinga
Keefe, Bruyette & Woods boosted the price target for Evercore Inc. (NYSE: EVR ) from $132.5 to $137. Keefe, Bruyette & Woods analyst Matthew Moon maintained an Outperform rating. Evercore shares rose 1% to $133.07 on Thursday. UBS cut the price target for Humana Inc. (NYSE: HUM ) from $645 to $620. UBS analyst Kevin Caliendo maintained a Buy rating. Humana shares fell 2.2% to $501.83 on Thursday. Susquehanna boosted the price target for Alaska Air Group, Inc. (NYSE: ALK ) from $55 to $59. Susquehanna analyst Christopher Danely maintained a Positive rating. Alaska Air shares gained 0.6% to trade at $52.15 on Thursday. Baird raised the price target for O-I Glass, Inc. (NYSE: OI ) from $24 to $26.. … Full story available on Benzinga.com
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock 2023/02/02 02:51:59 Benzinga
BRISBANE, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc., (NASDAQGM: VERA , "Vera")), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its previously announced underwritten public offering of 14,285,715 shares of its Class A common stock at a price to the public of $7.00 per share. The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $100.0 million. In addition, Vera has granted the underwriters a 30-day option to purchase up to an additional 2,142,857 shares of Class A common stock at the public offering price less underwriting discounts and commissions. The offering is expected to close on February 6, 2023, subject to satisfaction of customary closing conditions. J.P. Morgan, Cowen and Evercore ISI are acting as joint book-running managers for the proposed offering.
関連キーワード （投資銀行_証券サ―ビス 米国株 EVERCORE INC EVR ）
世界的な金融危機からの離脱とアベノミクスによる景気回復を受けて、証券業界には追い風が吹いている。また、14年1月のNISA(少額投資非課税制度)スタートで「貯蓄から投資へ」の流れも定着するとの期待が高い。一方で、世界的な規制強化に対応するためのコスト負担も増えており、トップラインの拡大への投資が今後の鍵となりそうだ。
「投資銀行」は、企業が資金調達のために発行する株式や債券の引き受けを主な業務とし、M&Aの仲介や資産の証券化など財務戦略に関するアドバイスを行う金融機関。日本の大手証券会社や銀行グループも投資銀行業務を行っている。
個人や企業から預金を集めて、それを企業や個人に融資をする金融機関。営業基盤が全国規模の都市銀行、営業基盤が一地方に限定された地方銀行、顧客の財産管理の代行が主要業務である信託銀行などがある。
「投資銀行」は、企業が資金調達のために発行する株式や債券の引き受けを主な業務とし、M&Aの仲介や資産の証券化など財務戦略に関するアドバイスを行う金融機関。日本の大手証券会社や銀行グループも投資銀行業務を行っている。
個人や企業から預金を集めて、それを企業や個人に融資をする金融機関。営業基盤が全国規模の都市銀行、営業基盤が一地方に限定された地方銀行、顧客の財産管理の代行が主要業務である信託銀行などがある。